- $67.73m
- $94.36m
- ILS355.55m
- 60
- 80
- 69
- 80
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.54 | ||
| Price to Tang. Book | 1.05 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.69 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -7.41% | ||
| Return on Equity | -12.96% | ||
| Operating Margin | -11.69% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ILSm | 8.93 | 65.03 | 219.68 | 388.68 | 355.55 | 335.11 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | +541.64 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.
Directors
- Ehud Barak CHM (79)
- Alexander Rabinovitch CEO (50)
- Asher Zamir VFN (45)
- Yisrael Gewirtz OTH (44)
- Avner Barak DRC (59)
- David Grossman DRC (46)
- Moshe Misgav DRC (41)
- Elan Shaham DRC (72)
- Yoram Even NED (47)
- Lennie Grinbaum Michelson NED (39)
- Gideon Hirschfeld NED (52)
- David Salton IND (66)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 20th, 1994
- Public Since
- July 26th, 2007
- No. of Employees
- 270
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 45,765,420
- Address
- Medinat HaYehudim 85, HERZLIYA, 4676670
- Web
- https://www.intercure.co/
- Phone
- +972 732207002
- Auditors
- Somekh Chaikin KPMG.
Upcoming Events for INCR
Similar to INCR
Airsculpt Technologies
NASDAQ Global Market
Biodesix
NASDAQ Global Market
Burning Rock Biotech
NASDAQ Global Market
Exagen
NASDAQ Global Market
Fulgent Genetics
NASDAQ Global Market
FAQ
As of Today at 21:19 UTC, shares in InterCure are trading at $1.48. This share price information is delayed by 15 minutes.
Shares in InterCure last closed at $1.48 and the price had moved by -43.94% over the past 365 days. In terms of relative price strength the InterCure share price has underperformed the S&P500 Index by -48.25% over the past year.
The overall consensus recommendation for InterCure is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreInterCure does not currently pay a dividend.
InterCure does not currently pay a dividend.
InterCure does not currently pay a dividend.
To buy shares in InterCure you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.48, shares in InterCure had a market capitalisation of $67.73m.
Here are the trading details for InterCure:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: INCR
Based on an overall assessment of its quality, value and momentum InterCure is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in InterCure is $9.31. That is 529.14% above the last closing price of $1.48.
Analysts covering InterCure currently have a consensus Earnings Per Share (EPS) forecast of -ILS1.48 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like InterCure. Over the past six months, its share price has underperformed the S&P500 Index by -8.24%.
As of the last closing price of $1.48, shares in InterCure were trading -13.68% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The InterCure PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
InterCure's management team is headed by:
- Ehud Barak - CHM
- Alexander Rabinovitch - CEO
- Asher Zamir - VFN
- Yisrael Gewirtz - OTH
- Avner Barak - DRC
- David Grossman - DRC
- Moshe Misgav - DRC
- Elan Shaham - DRC
- Yoram Even - NED
- Lennie Grinbaum Michelson - NED
- Gideon Hirschfeld - NED
- David Salton - IND